A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04)
A Phase III Randomized Controlled Clinical Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04)
This trial is a registrational Phase III, randomized, open-label, multicenter study designed to compare the efficacy and safety of BL-B01D1 in combination with a PD-1 monoclonal antibody versus nab-paclitaxel in combination with a PD-1 monoclonal antibody in patients with PD-L1-positive, previously untreated, inoperable locally advanced or recurrent metastatic triple-negative breast cancer.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究連絡先
- 名前：Sa Xiao, PHD
- 電話番号：+8615013238943
- メール：xiaosa@baili-pharm.com
研究場所
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国
- 募集
- Fudan University Shanghai Cancer Center
-
コンタクト：
- Jiong Wu
-
主任研究者：
- Jian Zhang
-
主任研究者：
- Jiong Wu
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Voluntarily sign the informed consent form and agree to comply with the protocol requirements;
- Female patients aged 18 to 75 years;
- Expected survival time ≥ 3 months;
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
- Pathologically confirmed recurrent or metastatic triple-negative breast cancer;
- Confirmed PD-L1 expression positivity by central laboratory testing;
- No prior systemic anti-tumor therapy in the advanced/recurrent or metastatic setting;
- Agree to provide archived tumor tissue specimens (surgical specimens) or fresh tissue samples from primary or metastatic lesions obtained within 3 years;
- Must have at least one measurable lesion as defined by RECIST v1.1;
- Toxicities from prior anti-tumor therapy must have recovered to ≤ Grade 1 as defined by NCI-CTCAE v6.0;
- No severe cardiac dysfunction, with left ventricular ejection fraction (LVEF) ≥ 50%;
- Organ function levels must meet the protocol-specified requirements;
- Urine protein ≤ 1+ or < 1000 mg/24 h;
- For premenopausal women of childbearing potential, a pregnancy test (serum) must be performed within 7 days before starting treatment, and pregnancy must be ruled out; patients must not be lactating. All enrolled patients (regardless of sex) must use adequate barrier contraception throughout the entire treatment period and for 7 months after the end of treatment.
Exclusion Criteria:
- Received surgery, radical radiotherapy, or immunotherapy within 4 weeks before the first dose;
- Prior exposure to ADC drugs with topoisomerase I inhibitor payload;
- Prior treatment with other T-cell receptor-targeting agents (excluding PD-1/PD-L1);
- Use of immunomodulators within 14 days before the first study drug dose;
- History of severe cardiac or cerebrovascular disease;
- Receiving chronic systemic corticosteroids at >10 mg/day prednisone before the first dose;
- Active autoimmune or inflammatory disease;
- Any thrombotic event within 6 months before randomization;
- Prolonged QTc, complete left bundle branch block, or similar;
- Active malignancy diagnosed within 3 years before randomization;
- Hypertension uncontrolled by two antihypertensives;
- Poorly controlled diabetes/hyperglycemia;
- History of steroid-treated ILD/interstitial pneumonitis;
- Concurrent lung disease causing clinically significant respiratory impairment;
- Active CNS metastases;
- Severe infection within 4 weeks before randomization;
- Massive or symptomatic serosal effusion;
- Severe non-healing wound, ulcer, or fracture within 4 weeks before consent;
- Clinically significant bleeding or bleeding tendency within 4 weeks before consent;
- Inflammatory bowel disease, extensive bowel resection, immune enteritis, bowel obstruction, or chronic diarrhea;
- Allergy or contraindication to the study drug;
- History of autologous/allogeneic stem cell transplantation;
- HIV antibody positive, active HBV, or active HCV;
- History of severe neurological or psychiatric illness;
- Received or planning to receive live vaccine within 28 days before randomization;
- Other conditions rendering the patient unsuitable per investigator's judgment.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：BL-B01D1+PD-1 monoclonal antibody
Participants receive BL-B01D1+PD-1 monoclonal antibody in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons. |
Administration by intravenous infusion for a cycle of 3 weeks.
他の名前：
Administration by intravenous infusion for a cycle of 3 weeks. |
|
アクティブコンパレータ：nab-paclitaxel+PD-1 monoclonal antibody
Participants receive nab-paclitaxel+PD-1 monoclonal antibody in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons. |
Administration by intravenous infusion for a cycle of 3 weeks. Administration by intravenous infusion for a cycle of 3 weeks. |
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
BICR-assessed Progression-free Survival (PFS)
時間枠：Up to approximately 24 months
|
Progression-free survival (PFS) as assessed by BICR is defined as the time between the date subjects were randomized and the first observation of disease progression (based on BICR's image-based assessment) or death. |
Up to approximately 24 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall Survival (OS)
時間枠：Up to approximately 24 months
|
Overall survival (OS) is defined as the time between the day the subject is randomized and the subject's death. |
Up to approximately 24 months
|
|
Investigator-assessed Progression-free Survival (PFS)
時間枠：Up to approximately 24 months
|
Investigator-assessed progression-free survival (PFS) per RECIST v1.1 is defined as the time from treatment initiation until the first documented disease progression according to RECIST v1.1 criteria, or death from any cause, whichever occurs first, as determined by the local treating investigator. |
Up to approximately 24 months
|
|
Objective Response Rate (ORR)
時間枠：Up to approximately 24 months
|
Objective response rate (ORR) is defined as the number of CR and PR in the treatment and control groups divided by the number of that group in the full analysis set (FAS). |
Up to approximately 24 months
|
|
Disease Control Rate (DCR)
時間枠：Up to approximately 24 months
|
Disease Control Rate (DCR) : Percentage of all randomized subjects who rated the best overall response (BOR) as complete response (CR), partial response (PR), and disease stabilization (SD) according to RECIST 1.1 criteria. |
Up to approximately 24 months
|
|
Duration of Response (DOR)
時間枠：Up to approximately 24 months
|
Duration of Response (DOR) : defined as the period from the date when tumor response is first recorded to the date when objective tumor progression is first recorded or the date of death. |
Up to approximately 24 months
|
|
Time to Response (TTR)
時間枠：Up to approximately 24 months
|
Time to Response (TTR) is defined as the time from randomization to the first documented response (CR or PR) according to RECIST v1.1 criteria. |
Up to approximately 24 months
|
|
Treatment Emergent Adverse Event (TEAE)
時間枠：Up to approximately 24 months
|
TEAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally emerging, or any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition during the treatment of BL-B01D1. The type, frequency and severity of TEAE will be evaluated during the treatment of BL-B01D1. |
Up to approximately 24 months
|
|
Cmax
時間枠：Up to approximately 24 months
|
Maximum serum concentration (Cmax) of BL-B01D1 will be investigated. |
Up to approximately 24 months
|
|
Tmax
時間枠：Up to approximately 24 months
|
Time to maximum serum concentration (Tmax) of BL-B01D1 will be investigated. |
Up to approximately 24 months
|
|
T1/2
時間枠：Up to approximately 24 months
|
Half-life (T1/2) of BL-B01D1 will be investigated. |
Up to approximately 24 months
|
|
AUC0-t
時間枠：Up to approximately 24 months
|
AUC0-t is defined as area under the serum concentration-time curve from time 0 to the time of the last measurable concentration. |
Up to approximately 24 months
|
|
CL (Clearance)
時間枠：Up to approximately 24 months
|
CL in the serum of BL-B01D1 per unit of time will be investigated. |
Up to approximately 24 months
|
|
Ctrough
時間枠：Up to approximately 24 months
|
Ctrough is defined as the lowest serum concentration of BL-B01D1 prior to the next dose will be administered. |
Up to approximately 24 months
|
|
Anti-drug Antibody (ADA)
時間枠：Up to approximately 24 months
|
Frequency of anti-BL-B01D1 antibody (ADA) will be investigated. |
Up to approximately 24 months
|
|
Neutralizing Antibody(NAb)
時間枠：Up to approximately 24 months
|
Frequency of anti-BL-B01D1 neutralizing antibodies will be investigated. |
Up to approximately 24 months
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- BL-B01D1-325
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。